WHO ICTRP trial
A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given…
EUCTR2017-002454-36-SE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-002454-36-SE |
|---|---|
| Public title | A Clinical Trial to compare the effectiveness of the study drug IMO-2125 given in combination with Ipilimumab (a drug indicated for the treatment of advanced melanoma) compared to Ipilimumab given alone in subjects with Refractory Melanoma |
| Scientific title | A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma |
| Primary sponsor | Idera Pharmaceuticals, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | United States;France;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;United Kingdom;Italy;Sweden |
| Conditions | Refractory melanoma is a malignant tumor of melanocytes which originates predominantly from skin. MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864 ;Therapeutic area… |
| Interventions | Product Name: IMO-2125 Product Code: IMO-2125 Pharmaceutical Form: Solution for injection INN or Proposed INN: tilsotolimod Current Sponsor code: tilsotolimod Other descriptive name: IMO-2125 Concentration unit: mg/ml… |
| Registration date | Mar 13, 2018 |
| Target size | 454 |
| Secondary IDs | 2125-MEL-301;125515 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: